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Abstract
IMPORTANCE Tumor measurements can be used to estimate time to nadir and depth of nadir as
potential surrogates for overall survival (OS).
OBJECTIVE To assess time to nadir and depth of nadir as surrogates for OS in metastatic
colorectal cancer.
DESIGN, SETTING, AND PARTICIPANTS Pooled analysis of 20 randomized clinical trials within the
Aide et Recherche en Cancerologie Digestive database, which contains academic and industry-
sponsored trials, was conducted. Three sets of comparisons were performed: chemotherapy alone,
antiangiogenic agents, and anti–epidermal growth factor receptor agents in first-line treatment for
patients with metastatic colorectal cancer.
MAINOUTCOMES ANDMEASURES Surrogacy of time to nadir and depth of nadir was assessed at
the trial level based on joint modeling of relative tumor-size change vs baseline and OS. Treatment
effects on time to nadir and on depth of nadir were defined in terms of between-arm differences in
time to nadir and in depth of nadir, and both were assessed in linear regressions for their correlation
with treatment effects (hazard ratios) on OS within each set. The strengths of association were
quantified using sample-size–weighted coefficients of determination (R2), with values closer to 1.00
indicating stronger association. At the patient level, the correlationwas assessed betweenmodeled
relative tumor-size change and OS.
RESULTS For 14 chemotherapy comparisons in 4289 patients, the R2 value was 0.63 (95% CI, 0.30-
0.96) for the association between treatment effects on time to nadir and OS and 0.08 (95% CI,
0-0.37) for depth of nadir and OS. For 11 antiangiogenic agent comparisons (4854 patients),
corresponding values of R2 were 0.25 (95% CI, 0-0.72) and 0.06 (95% CI, 0-0.35). For 8 anti–
epidermal growth factor receptor comparisons (2684 patients), corresponding values of R2 were
0.24 (95% CI, 0-0.83) and 0.21 (95% CI, 0-0.78).
CONCLUSIONS ANDRELEVANCE In contrast with early reports favoring depth of response as a
surrogate, these results suggest that neither time to nadir nor depth of nadir is an acceptable
surrogate for OS in the first-line treatment of metastatic colorectal cancer.
JAMA Network Open. 2019;2(9):e1911750. doi:10.1001/jamanetworkopen.2019.11750
Key Points
Question Can end points based on the
kinetics of tumor size after treatment be
used as surrogates for overall survival in
metastatic colorectal cancer?
Findings In this pooled analysis of data
from 20 randomized clinical trials, time
to nadir and depth of nadir were
modeled and assessed as potential
surrogates for overall survival at the
patient and trial levels. The associations
found were weak or moderate; there
were notable differences in tumor-size
kinetics between antiangiogenic agents
and anti–epidermal growth factor
receptor agents.
Meaning The implications of these
results for early drug development and
clinical practice are unclear and warrant
further studies; the findings of this study
reinforce the need to developmore
reliable end points that reflect tumor
biology and patient benefit.
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Introduction
The availability of active treatments for use in subsequent lines have called into question the use of
overall survival (OS) as a primary end point in phase 3 trials on first-line therapy for metastatic
colorectal cancer (mCRC).1 As a result, there has been a long-standing interest in developing and
validating surrogate end points for OS in this setting.2,3 Such validation requires demonstration of a
strong association between the surrogate and the final end point at the patient level (ie, patients with
improvements in the surrogate end point also tend to have improvements in the final end point) and
a strong association between the treatment effects on the surrogate end point and the final end
point (the trial-level association).4 Tumor-size–based end points have generated interest in the
search for early treatment end points in mCRC.5-9 These end points may be categorical or continuous
and, among the latter type, the end point receiving themost attention has been the depth of
response, defined as themaximum percent tumor shrinkage during treatment. In work published in
abstract form, the depth of response was found to be associated with OS at the patient level in
first-line cetuximab-based therapy.10 That study was based on 2 randomized trials and did not assess
the trial-level surrogacy. To obtain amore in-depth view of this question, we assessed the individual-
and trial-level surrogacy for OS of 2 continuous tumor-size–based end points in first-line treatment
of mCRC.
Methods
Trial Selection andDefinition of Contrasts
Tumormeasurements andOS datawere available from 20 first-line randomized clinical trials inmCRC
within the Aide et Recherche en Cancerologie Digestive (ARCAD) database (Table 1).11-30 To evaluate
the trial-level surrogacy, unbiased estimates of treatment effects are needed; hence, the clinical trial
database was used. While our analysis used data from several randomized clinical trials, it is not a
classic meta-analysis attempting to evaluate pooled estimates of treatment effects. As such, the
study follows the recently published Reporting of Surrogate Endpoint Evaluation Using Meta-
analyses (ReSEEM) Reporting Guidelines31 rather than the Preferred Reporting Items for Systematic
Reviews andMeta-analyses (PRISMA) guidelines.
Tumor measurements consisted of the longest diameters of target lesions, used in the original
trials according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline, version 1.1.32
Eight trials involved only chemotherapy; of the 12 trials that had at least 1 biological agent, 6
evaluated antiangiogenic (anti-ANG) agents as the only biological, 4 investigated an anti–epidermal
growth factor receptor (anti-EGFR) agent as the only biological, and 2 trials had both an anti-ANG and
anti-EGFR agent. The analysis was based on comparisons between 2 arms (henceforth termed
contrasts) nested within trials, with control and experimental arms defined according to historical
evolution. An exception to this rule was made for HORIZON III,24 for which the cediranib armwas
considered as control to have bevacizumab as the uniform experimental intervention for anti-ANG
agents (Table 1). For 8 trials with more than 2 arms, each experimental arm was compared with a
control arm created by randomly splitting the set of patients originally randomized to the control
arm. This procedure was applied to avoid including each patient twice in the analysis, which would
artificially induce a correlation that would confound the associations under investigation.
Statistical Analysis
Target lesions measured up to 24months after randomization were used, as 98% of the available
postbaseline measurements were made within 24 months. Individual trials had tumor-assessment
schedules that varied between 6 and 12 weeks, but this variation does not influence themodels used
here. Overall survival was defined as the time from randomization to death from any cause, with
censoring of data from patients who were alive at the last contact date. Separate analyses were
conducted for chemotherapy-only contrasts, anti-ANG-agent contrasts, and anti-EGFR-agent
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contrasts. Because KRAS (OMIM *190070) is a predictive biomarker for anti-EGFR treatment, only
patients with wild-type KRASwere considered in contrasts evaluating the effects of such treatments.
For trials of different treatment sequences, only contrasts for which the 2 arms testing different
regimens at the beginning of the treatment sequence were analyzed. For the Bolus, Infusional, or
CapecitabineWith Camptosar-Celecoxib trial,12 treatment arms with celecoxib were not analyzed.
Table 1. Control and Experimental Arms for the 3 Treatment Classes Included in the Analysis
Study Contrast
Treatment (Sample Size, No.)a,b
Control Experimental
Chemotherapy Alone (n = 4289)
Díaz-Rubio et al,11 2007 03-TTD-01 FUOX (136) XELOX (137)
Fuchs et al,12 2007 BICC-C A FOLFIRI (28) Modified IFL (61)
Fuchs et al,12 2007 BICC-C B FOLFIRI (27) CAPIRI (54)
Tournigand et al,13 2004 C97-3 FOLFIRI→ FOLFOX6 (79) FOLFOX6→ FOLFIRI (86)
Koopman et al,14 2007 CAIRO1 Capecitabine→ irinotecan→ XELOX (295) CAPIRI→ XELOX (291)
Seymour et al,15 2007 FOCUS A Fluorouracil/leucovorin→ irinotecan (231) FOLFIRI (231)
Seymour et al,15 2007 FOCUS B Fluorouracil/leucovorin→ I (227) FOLFOX (235)
Seymour et al,16 2011 FOCUS2 A Fluorouracil/leucovorin (74) FOLFOX (80)
Seymour et al,16 2011 FOCUS2 B Capecitabine (77) XELOX (78)
Falcone et al,17 2007 GONO FOLFIRI (33) FOLFOXIRI (46)
Saltz et al,18 2008 N016966 A FOLFOX4 (284) XELOX (284)
Saltz et al,18 2008 N016966 B FOLFOX4 (160) XELOX (162)
Goldberg et al,19 2004 N9741 A IFL (149) FOLFOX (300)
Goldberg et al,19 2004 N9741 B rIFL (171) Irinotecan, oxaliplatin (273)
Antiangiogenic Agents (n = 4854)
Tebbutt et al,20 2010 AGITG (MAX) A Capecitabine (75) Capecitabine + bevacizumab (140)
Tebbutt et al,20 2010 AGITG (MAX) B Capecitabine (68) Capecitabine + bevacizumab + mitomycin C (138)
Hurwitz et al,21 2004 AVF2107g A IFL (187) IFL + bevacizumab (363)
Hurwitz et al,21 2004 AVF2107g B IFL (176) Fluorouracil/leucovorin + bevacizumab (98)
Kabbinavar et al,22 2005 AVF2192g Fluorouracil/leucovorin (80) Fluorouracil/leucovorin + bevacizumab (95)
Hoff et al,23 2012 HORIZON II A FOLFOX/XELOX (171) FOLFOX/XELOX + cediranib (474)
Hoff et al,23 2012 HORIZON II B FOLFOX/XELOX (170) FOLFOX/XELOX + cediranib (198)
Schmoll et al,24 2012 HORIZON III A FOLFOX + cediranib (654) FOLFOX + bevacizumab (329)
Schmoll et al,24 2012 HORIZON III B FOLFOX + cediranib (172) FOLFOX + bevacizumab (330)
Saltz et al,18 2008 N016966 C FOLFOX4 (161) FOLFOX4 + bevacizumab (310)
Saltz et al,18 2008 N016966 D XELOX (156) XELOX + bevacizumab (309)
Anti-EGFR Agents (n = 2684)
Tol et al,25 2009 CAIRO2 CAPOX + bevacizumab (126) CAPOX + bevacizumab + cetuximab (128)
Maughan et al,26 2011 COIN A Fluorouracil/leucovorin/oxaliplatin (99) Fluorouracil/leucovorin/oxaliplatin + cetuximab (82)
Maughan et al,26 2011 COIN B Capecitabine/oxaliplatin (189) Capecitabine/oxaliplatin + cetuximab (184)
Van Cutsem et al,27 2009 CRYSTAL FOLFIRI (324) FOLFIRI + cetuximab (291)
Bokemeyer et al,28 2009 OPUS FOLFOX (88) FOLFOX + cetuximab (76)
Hecht et al,29 2009 PACCE (C249) A Oxaliplatin based + bevacizumab (188) Oxaliplatin based + bevacizumab + panitumumab (178)
Hecht et al,29 2009 PACCE (C249) B Irinotecan based + bevacizumab (51) Irinotecan based + bevacizumab + panitumumab (50)
Douillard et al,30 2010 PRIME (C203) FOLFOX4 (318) FOLFOX4 + panitumumab (312)
Abbreviations: AGITG, Australasian Gastro-Intestinal Cancer Trials Group; anti-EGFR,
anti–epidermal growth factor receptor; BICC, Bolus, Infusional, or CapecitabineWith
Camptosar-Celecoxib; CAPIRI, capecitabine, irinotecan; CAPOX, capecitabine,
oxaliplatin; FOCUS, Fluoxetine or Control Under Supervision; FOLFIRI, fluorouracil,
leucovorin, irinotecan; FOLFOX, fluorouracil, leucovorin, oxaliplatin; FOLFOXIRI,
fluorouracil, leucovorin, oxaliplatin, irinotecan; FUOX, fluorouracil, oxaliplatin; GONO,
Gruppo Oncologico Nord Ovest; IFL, irinotecan, fluorouracil, leucovorin; MAX,
Mitomycin C, Avastin and Xeloda; rIFL, reduced-dose irinotecan, fluorouracil, leucovorin;
PACCE, Panitumumab Advanced Colorectal Cancer Evaluation; PRIME, Panitumumab
Randomized Trial in CombinationWith Chemotherapy for Metastatic Colorectal Cancer
to Determine Efficacy; TTD, Spanish Cooperative Group for Gastrointestinal Tumor
Therapy; XELOX, capecitabine, oxaliplatin; and→, subsequently.
a Sample sizes may differ from those reported in the original publications owing to
exclusion of patients in the present analysis (see Methods section for details).
b Numbers with the combination regimens (eg, FOLFOX6) are used by the original
developers of these regimens to denote subsequent versions and improvements in the
administration schedule.
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Tumor-size measurements (the sum of all target lesions) were modeled using the relative
tumor-size change (RTSC) vs baseline, defined (for time t) as follows: RTSC(t) = (tumor size at
time t – tumor size at baseline) / (tumor size at baseline).
Repeated values of RTSC and the time to death were analyzed in joint models.33,34 In particular,
RTSCmeasures were analyzed by linear mixed-effects models with contrast-specific fixed and
random linear and square-root time effects. Overall survival was analyzed by proportional hazards
models that included the random effects from the RTSC model to account for the association
between RTSC and survival time. Based on the joint models, treatment effects on RTSC and OSwere
estimated. For OS, the effects were estimated using the natural logarithm of the hazard ratio (HR)
obtained from the proportional hazards model (logHR). For RTSC, the outcomes were defined based
on themean treatment-specific time profiles estimated using the linear mixed-effects model. In
particular, for each profile, the nadir (ie, the local minimum RTSC value) was obtained, together with
the time at which the nadir took place. Treatment effects were then defined in terms of differences
in time to nadir and differences in depth of nadir; the latter variable is analogous to depth of response
but is estimated from themodel rather than coming directly from patient data. Figure 1 illustrates
Figure 1. Longitudinal Profiles
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A, Relative tumor-size changes over time for individual patients and themodel-based
estimated profile for the control group. B, Relative tumor-size changes over time for
individual patients and themodel-based estimated profile for the experimental group. C,
Based on the model-based profiles, the nadir for the control arm is estimated to occur
at 5.8 months, with the depth of nadir −0.38 (ie, a 38% reduction of the tumor mass
relative to baseline). Corresponding figures for the experimental arm are 5.1 months for
the time of occurrence of the nadir and −0.27 (ie, 27% reduction of the tumor mass
relative to baseline) for the depth of nadir. Consequently, the effect of experimental
treatment in terms of time to nadir and depth of nadir is equal to 5.1 − 5.8 = -0.7 months
and −0.27 − (−0.38) = 0.11. That is, in the experimental arm, the nadir occurs earlier and
is 11% smaller (ie, less deep) than in the control arm.
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the calculation of longitudinal profiles for 1 of the contrasts. For differences in time to nadir, negative
values indicate that the nadir occurs earlier with experimental treatment; for differences in depth of
nadir, negative values indicate that the nadir is deeper with experimental treatment.
To assess the validity of time to nadir and depth of nadir as surrogates for OS, we applied the
correlation approach.33 Specifically, a linear regression was fitted to the estimated pairs of treatment
effects on time to nadir or depth of nadir and OS. The regression was weighted by the contrast-
specific sample size. The coefficient of determination (R2) was used to quantify the strength of
association at the trial level between the treatment effects on time to nadir or depth of nadir and OS.
An R2 value greater than 0.75was considered an indicator of good surrogacy.35,36We also quantified
the strength of association at the individual level between RTSC andOS.With this aim, wemeasured
the correlation between the individual random effects included in the linear mixed-effects model for
RTSC and the proportional hazards model for OS using a correlation coefficient, denoted by R(t).33
This correlation coefficient is a time-dependent measure, since the association between RTSC and
the death process can be defined relative to any time over the course of tumor-size measurements.
In the analysis, 2-sided 95% CIs were used. Analyses were conducted with SAS, version 9.4 (SAS
Institute Inc) and Stata, version 13.1 (StataCorp LLC).
Results
ChemotherapyAlone
There were 6224 patients in the ARCAD database enrolled in 9 trials eligible for this analysis (8 trials
involving only chemotherapy and 1 trial that included bevacizumab but provided chemotherapy-
alone contrasts). After excluding patients without any tumor-size information or with tumor-size
measurements available only more than 24months after randomization, 4289 patients (68.9%)
could be analyzed (Table 1). Such patients were grouped in 14 contrasts, with themedian follow-up
per trial ranging from 14 to 128months. eFigure 1A in the Supplement presents the Kaplan-Meier OS
curves for these 14 contrasts, with the corresponding HRs presented in Table 2.
eFigure 2A in the Supplement presents the estimated, model-based longitudinal profiles for
each contrast in these trials. The corresponding estimates of treatment effects in terms of the
differences in time to nadir and depth of nadir are presented in Table 2. There was large variability in
the treatment effects, reflecting relatively small and inconsistent differences in the longitudinal
profiles (eFigure 2A in the Supplement). For instance, for time to nadir, the estimated treatment
effects varied (Table 2) from −4.53months (BICC-C C) to 4.77 months (Gruppo Oncologico Nord
Ovest). For depth of nadir, the range was from −0.49 (FOCUS B) to 0.17 (BICC-C C). For 1 comparison
(FOCUS2 B), the effects could not be obtained because the estimated RTSC profile for the
experimental arm did not reach a local minimum (the profile was a strictly increasing function
of time).
The associations between the differences in time to nadir and logHRs for OS, as well as between
the differences in depth of nadir and logHRs for OS, are presented in Figure 2, with a weighted
regression line. The estimated value of R2 was 0.63 (95% CI, 0.30-0.96) for the association between
the treatment effects on time to nadir and OS, and 0.08 (95% CI, 0-0.37) for the association
between the treatment effects on depth of nadir and OS. eFigure 3A in the Supplement presents the
estimated values of R(t) that quantify the association at the individual level between RTSC and OS
at time t. At all considered time points, R(t) values were 0.9 or larger. Thus, the plot indicates that
RTSC values providemuch information on a patient's OS.
Anti-ANGAgents
For anti-ANG agent contrasts, data on 5390 patients enrolled in 6 trials were available for analysis.
After excluding patients with no tumor-size information or with tumor-size measurements available
only more than 24months after randomization, 4854 (90.1%) of the patients could be analyzed
(Table 1). Eleven contrasts could be formed, with median follow-up in each trial ranging from 14 to 31
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months. eFigure 1B in the Supplement shows the OS curves for each of these contrasts, and the
corresponding HRs are presented in Table 2. eFigure 2B in the Supplement presents the longitudinal
RTSC profiles for these contrasts, and the corresponding estimates of treatment effects on time to
nadir and on depth of nadir are presented in Table 2. All effects on time to nadir were positive,
suggesting that the nadir for the experimental treatments took place later than for the control
treatments. At the same time, all but 2 (for HORIZON III A and N016966 C) effects on depth of nadir
Table 2. Estimated Time to Nadir and Depth of Nadir
Contrast
Time to Nadir, moa Depth of Nadir, mb
HR for OSdControl Experimental Treatment Effectc Control Experimental Treatment Effectc
Chemotherapy Alone
03-TTD-01 5.81 5.09 −0.72 −0.38 −0.27 0.11 1.06
BICC-C A 5.89 5.26 −0.64 −0.32 −0.36 −0.04 1.07
BICC-C C 11.04 6.52 −4.52 −0.46 −0.29 0.17 1.57
C97-3 5.32 4.82 −0.50 −0.40 −0.34 0.06 0.83
CAIRO1 2.72 3.73 1.01 −0.06 −0.24 −0.18 0.80
FOCUS A 0.66 3.05 2.39 −0.12 −0.09 0.02 0.88
FOCUS B 2.97 2.70 −0.27 0.23 −0.26 −0.49 0.93
FOCUS2 A 1.17 2.00 0.83 0.40 −0.07 −0.47 1.01
FOCUS2 B 0.05 NA NA − 0.01 NA NA 0.99
GONO 6.37 11.14 4.77 −0.43 −0.66 −0.23 0.78
N016966 A 5.25 4.82 −0.43 −0.38 −0.40 −0.02 0.89
N016966 B 6.17 4.59 −1.58 −0.43 −0.36 0.07 1.16
N9741 A 4.66 7.31 2.65 −0.28 −0.44 −0.16 0.68
N9741 B 4.57 4.75 0.18 −0.24 −0.27 −0.01 0.90
Antiangiogenic Agents
AGITG (MAX) A 3.42 4.13 0.70 −0.15 −0.26 −0.11 0.88
AGITG (MAX) B 3.05 4.82 1.78 −0.11 −0.28 −0.17 1.07
AVF2107g A 4.02 6.34 2.32 −0.26 −0.37 −0.11 0.73
AVF2107g B 3.66 6.66 2.99 −0.21 −0.27 −0.06 0.80
AVF2192g 3.88 4.51 0.63 −0.24 −0.26 −0.02 0.91
HORIZON II A 4.98 5.28 0.30 −0.38 −0.39 −0.01 0.88
HORIZON II B 4.56 5.93 1.37 −0.32 −0.41 −0.09 0.96
HORIZON III A 5.70 6.64 0.93 −0.35 −0.35 0.00 1.09
HORIZON III B 5.38 5.92 0.54 −0.30 −0.34 −0.04 1.00
N016966 C 5.37 6.79 1.42 −0.37 −0.36 0.01 0.85
N016966 D 4.93 6.04 1.10 −0.33 −0.36 −0.03 0.82
Anti-EGFR Agents
CAIRO2 6.78 5.21 −1.57 −0.26 −0.33 −0.07 1.13
COIN A 6.37 8.34 1.97 −0.31 −0.40 −0.09 0.76
COIN B 5.82 2.97 −2.85 −0.03 −0.30 −0.27 1.09
CRYSTAL 6.28 8.26 1.98 −0.31 −0.46 −0.16 0.74
OPUS 7.83 10.23 2.40 −0.34 −0.55 −0.22 0.86
PACCE (C249) A 7.40 7.77 0.37 −0.37 −0.31 0.06 1.48
PACCE (C249) B 171.1 7.99 −163.1 −0.78 −0.37 0.41 1.76
PRIME (C203) 8.36 9.22 0.86 −0.40 −0.48 −0.08 0.81
Abbreviations: AGITG, Australasian Gastro-Intestinal Cancer Trials Group; anti-EGFR,
anti–epidermal growth factor receptor; BICC, Bolus, Infusional, or CapecitabineWith
Camptosar-Celecoxib; FOCUS, Fluoxetine or Control Under Supervision; GONO, Gruppo
Oncologico Nord Ovest; HR, hazard ratio; OS, overall survival; PACCE, Panitumumab
Advanced Colorectal Cancer Evaluation; PRIME, Panitumumab Randomized Trial in
CombinationWith Chemotherapy for Metastatic Colorectal Cancer to Determine
Efficacy; TTD, Spanish Cooperative Group for Gastrointestinal Tumor Therapy.
a For differences in time to nadir, negative values indicate that the nadir occured earlier
with experimental treatment.
b For differences in depth of nadir, negative values indicate that the nadir was deeper
with experimental treatment.
cExperimental minus control.
dHazard ratios may differ from those reported in the original publications owing to
exclusion of patients in the present analysis and the use of a different modeling
framework (a joint model for relative tumor-size change and OS).
JAMANetworkOpen | Oncology Tumor-Size–Based End Points as Surrogates for Overall Survival in Metastatic Colorectal Cancer Trials
JAMA Network Open. 2019;2(9):e1911750. doi:10.1001/jamanetworkopen.2019.11750 (Reprinted) September 20, 2019 6/14
Downloaded From: https://jamanetwork.com/ on 01/20/2020
were negative, suggesting that the experimental treatments led to a larger relative reduction in
tumor size than the control treatments. This finding reflects that the RTSC profiles for the control
arms exhibited a higher curvature than the profiles for the experimental arms (eFigure 2B in the
Supplement).
Figure 2. Trial-Level Associations Between Treatment Effects
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The associations between treatment effects on time to nadir and depth of nadir and on OS are
shown in Figure 2B. The estimated value of R2 was 0.25 (95%CI, 0-0.72) for the association between
the treatment effects on time to nadir andOS and0.06 (95%CI, 0-0.35) for the association between
the treatment effects on depth of nadir andOS. eFigure 3B in the Supplement depicts the association
at the individual level between RTSC and OS at time t. Values of R(t) become larger than 0.9 for t of
approximately 6 months. Thus, the plot suggests that, initially, RTSC values provided relatively little
information on a patient's OS. However, as additional information on tumor size was gathered over
time during the first year of treatment, RTSC achieved a better predictive strength for OS, with no
further gain in the subsequent year.
Anti-EGFRAgents
Of 3081 eligible patients enrolled in 6 trials involving anti-EGFR agents, 2684 patients (87.1%) could
be analyzed after excluding those without any tumor-size information or with tumor-size
measurements available only more than 24months after randomization (Table 1). These patients
were grouped into 8 contrasts, and themedian follow-up in each trial ranged from 10 to 47months.
eFigure 1C in the Supplement presents the OS curves for these contrasts. The corresponding HRs are
reported in Table 2. eFigure 2C in the Supplement presents the longitudinal RTSC profiles for these
contrasts, and the corresponding estimates of the treatment effects on time to nadir and depth of
nadir are given in Table 2. Although the effects on time to nadir show some heterogeneity (range
from −2.85 for COIN B to 2.40 for OPUS, excluding PACCE [C249] B), once again, all but 2 (for PACCE
[C249] A and B) of the effects on depth of nadir were negative, suggesting that the experimental
treatments led to larger tumor shrinkage than the control treatments. This finding reflects that the
RTSC profiles for the experimental arms seem to be shifted down as compared with the control-arm
profiles, while exhibiting roughly a similar curvature (eFigure 2C in the Supplement). An exception
was the PACCE B comparison, for which the estimated RTSC profile for the control arm decreased,
unlike for the experimental arm. As a consequence, the estimated time to nadir for the control arm
was long (equal to 171.1 months) and resulted in treatment effects on time to nadir (−163.1) and depth
of nadir (0.41) that were markedly different from the other comparisons (Table 2).
The associations between treatment effects are depicted in Figure 2E and F. All comparisons
were taken into account, and the estimated value of R2 was 0.24 (95%CI, 0-0.83) for the association
between the treatment effects on time to nadir andOS and0.21 (95%CI, 0-0.78) for the association
between the treatment effects on depth of nadir and OS. When the PACCE B comparison was
excluded from the analysis, the estimates of R2 were 0.36 (95% CI, 0-0.97) for depth of nadir and
0.18 (95% CI, 0-0.74) for OS. eFigure 3C in the Supplement depicts the individual-level association
between RTSC and OS at time t. At all considered time points, values of R(t) are smaller than 0.4,
suggesting that RTSC provided little information on a patient's OS.
Discussion
Given the continuum of care in mCRC, it becomes increasingly difficult to demonstrate gains in OS in
first-line treatment trials. This difficulty has heightened interest in alternative strategies, such as
adaptive designs37 and the use of surrogate end points, including those based on tumor
measurements. The latter approach is contrary to the key finding from the present study that neither
time to nadir nor depth of nadir can be considered a valid surrogate for OS using contemporary
regimens for first-line therapy of mCRC. At best, time to nadir appears to display a moderate
association with OS at the trial level with chemotherapy alone or combined with an anti-ANG agent,
while depth of nadir appears to display a weak association with OS in all treatment classes. Another
finding from this study is the apparent difference between the response kinetics of regimens that
include an anti-ANG agent and those that involve an anti-EGFR agent.
The difference in tumor-growth kinetics between anti-ANG and anti-EGFR agents may warrant
further exploration. Data presented in Table 2 and eFigure 2 in the Supplement suggest that the
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addition of an anti-ANG agent to chemotherapy is associated with a later, although not often deeper,
nadir. Conversely, the addition of an anti-EGFR agent often produces a deeper nadir, with less-
conclusive results about its timing of occurrence. These exploratory observations are based on a
relatively small number of contrasts, but theymay support the clinical impression that the addition
of an anti-EGFR agent produces a larger influence on the depth of responses than the addition of an
anti-ANG agent. Albeit subject to bias owing to the above-mentioned reasons, the often-divergent
slopes after nadir between control and experimental arms as shown in eFigure 2 in the Supplement
suggest that the tumor-growth kinetics with both classes of agents are not marked by a rebound
effect after progression. The differences in tumor-growth kinetics among different classes of agents
are also reflected on the individual-level associations between the RTSC and OS processes. For
chemotherapy, it seems that RTSCmay provide a strong prediction of a patient’s survival. For
anti-ANG agents, a strong correlationmight be inferred after the initial half-year of treatment.
However, for anti-EGFR agents, the correlation appeared to be weak. These individual-level
estimates depend largely on the form of themodels applied and should be interpreted with caution.
Strengths and Limitations
Strengths of this study are the large sample size and representativeness in terms of contemporary
first-line therapy. Moreover, results of this study suggest that the dimensions of measurable tumor
lesions can bemodeled to provide information on tumor-growth kinetics. In this sense, our approach
differs from the one used byMansmann et al,10 who did not model tumor size as a function of time
and did not estimate trial-level associations, which is a current requirement for surrogacy
validation.38
This study has limitations. The chief limitation of this study is the absence of tumor
measurements for all patients, which is a potential source of bias through exclusion of individuals
with features that may differ systematically from those of included patients. Likewise, extended RAS
testing was not available at the time that these trials were conducted, leading to a predictably small
percentage of patients being falsely considered as having wild-type tumors. Moreover, no data were
available on tumor sidedness or other potential prognostic or predictive molecular markers, such as
the status of microsatellite instability, BRAF, or HER2. Limitations also apply to the model building,
which is affected by the absence of postprogression measurements. Moreover, if progression is due
to new lesions before the sumof target lesions has reached the nadir, there is increased uncertainty
in the estimation of time to nadir and depth of nadir. Also, new lesions could not be included in the
definition of RTSC, because the size of such lesions was not reported. In addition, the strength of the
association between treatment effects on time to nadir or depth of nadir and onOSwas assessed by
using a linear regression model weighted by the sample size to account for the uncertainty in the
estimated treatment effects. A methodologically more appropriate approach would be to take into
account estimates of the SEs and correlation of the estimated treatment effects.39 However,
obtaining such estimates for the jointmodel used in our analysis was not possible, because themodel
was fitted by using the expectation-maximization algorithm.
Conclusions
Neither time to nadir nor depth of nadir appears to be an acceptable surrogate for OS. These findings
are not surprising, given the weak trial-level association between conventional response rates and
OS inmCRC, despite their associationwith OS at the patient level, both inmCRC and advanced breast
cancer.40,41 This distinction indicates that achieving responsemay convey prognostic information
for patients in clinical practice, but at the same time suggests that response-based end points cannot
replace OS in clinical trials. In none of the treatment classes analyzed was the association between
treatment effects strong enough to warrant reasonable precision of the prediction of the treatment
effect on OS from the effect on time to nadir or depth of nadir. Such a reasonable precision of the
prediction is currently considered the key requirement for a surrogate end point.38 Nevertheless, at
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least for chemotherapy and targeted agents, the use of response-based end points in early-phase
trials has been helpful in selecting regimens for further testing in phase 3 trials. Moreover, in clinical
practice, a deeper responsemay help in controlling symptoms and increase the chance of performing
secondary resections. Therefore, the implications of these results for early drug development and
clinical practice are unclear and warrant further studies. In addition, the findings of this study
reinforce the need to developmore reliable end points that reflect tumor biology and patient benefit.
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